2026-05-20T03:33:33Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/226152025-05-08T12:51:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16939col_20.500.12105_16962col_20.500.12105_16967col_20.500.12105_16982

00925njm 22002777a 4500 dc Gallardo, E author Mendez-Vidal, MJ author Perez-Gracia, JL author Sepúlveda-Sánchez, Juan Manuel author Campayo, M author Chirivella-Gonzalez, I author Garcia-del-Muro, X author Gonzalez-del-Alba, A author Grande, E author Suarez, C author 2018-01 The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge. Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):47-56. Epub 2017 Nov 13. 10.1007/s12094-017-1765-4 1699-3055 1699-048X Clinical & Translational Oncology http://hdl.handle.net/20.500.13003/9457 29134564 L619234845 2-s2.0-85033583625 https://hdl.handle.net/20.500.12105/22615 423375400007 Kidney cancer Systemic therapy Molecular pathology SEOM clinical guideline for treatment of kidney cancer (2017)